Related Experiment Video
Updated: Jul 10, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Multimorbidity in atrial fibrillation for clinical implications using the Charlson Comorbidity Index
Moonki Jung1, Pil-Sung Yang2, Daehoon Kim1
1Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Insights
High comorbidity burden in atrial fibrillation patients increases antiplatelet use but decreases anticoagulant prescription. This multimorbidity significantly elevates risks for death, stroke, bleeding, and heart failure hospitalization.
Area of Science:
- Cardiology
- Geriatrics
- Public Health
Background:
- Predicting outcomes for atrial fibrillation (AF) patients with multiple comorbidities is complex.
- The Charlson Comorbidity Index (CCI) is a tool to assess multimorbidity.
- Understanding the clinical implications of high CCI in AF is crucial for patient management.
Purpose of the Study:
- To evaluate the association between high Charlson Comorbidity Index (CCI) and clinical outcomes in patients with new-onset atrial fibrillation (AF).
- To assess the impact of multimorbidity on antithrombotic treatment strategies in AF patients.
- To determine the risk stratification of adverse events based on CCI and AF status.
Main Methods:
- Analysis of 451,368 participants from the Korea National Health Insurance Service-Health Screening cohort (2002-2013).
- Categorization into new-onset AF and non-AF groups, with high CCI defined as ≥4.
- Evaluation of antithrombotic treatment and outcomes (all-cause death, stroke, major bleeding, heart failure hospitalization) over 9 years.
Main Results:
- Patients with high CCI (≥4) showed increased antiplatelet use (aOR 1.05) and decreased anticoagulant prescription (OR 0.97) in the AF group.
- Adverse event incidence increased progressively: low CCI without AF < high CCI without AF < low CCI with AF < high CCI with AF.
- High CCI with AF significantly elevated risks for all-cause death (aHR 2.52), stroke (aHR 1.43), major bleeding (aHR 1.14), and HF hospitalization (aHR 4.75) compared to low CCI without AF.
Conclusions:
- High CCI is a predictor of altered antithrombotic prescribing patterns in AF patients.
- Atrial fibrillation, particularly in the context of high comorbidity, substantially increases the risk of adverse cardiovascular and mortality outcomes.
- Risk stratification using CCI and AF status is essential for optimizing care in multimorbid patients.
Background:
Predicting survival in atrial fibrillation (AF) patients with comorbidities is challenging. This study aimed to assess multimorbidity in AF patients using the Charlson Comorbidity Index (CCI) and its clinical implications.
Methods:
We analyzed 451,368 participants from the Korea National Health Insurance Service-Health Screening cohort (2002-2013) without prior AF diagnoses. Patients were categorized into new-onset AF and non-AF groups, with a high CCI defined as ≥4 points. Antithrombotic treatment and outcomes (all-cause death, stroke, major bleeding, and heart failure [HF] hospitalization) were evaluated over 9 years.
Results:
In total, 9.5% of the enrolled patients had high CCI. During follow-up, 12,241 patients developed new-onset AF. Among AF patients, antiplatelet drug use increased significantly in those with high CCI (adjusted odds ratio [OR] 1.05, 95%confidence interval [CI] 1.02-1.08, P < .001). However, anticoagulants were significantly less prescribed in patients with high CCI (OR 0.97, 95%CI 0.95-0.99, P = .012). Incidence of adverse events (all-cause death, stroke, major bleeding, HF hospitalization) progressively increased in this order: low CCI without AF, high CCI without AF, low CCI with AF, and high CCI with AF (all P < .001). Furthermore, high CCI with AF had a significantly higher risk compared to low CCI without AF (all-cause death, adjusted hazard ratio [aHR] 2.52, 95% CI 2.37-2.68, P < .001; stroke, aHR 1.43, 95% CI 1.29-1.58, P < .001; major bleeding, aHR 1.14, 95% CI 1.04-1.26, P = .007; HF hospitalization, aHR 4.75, 95% CI 4.03-5.59, P < .001).
Conclusions:
High CCI predicted increased antiplatelet use and reduced oral anticoagulant prescription. AF was associated with higher risks of all-cause death, stroke, major bleeding, and HF hospitalization compared to high CCI.
More Related Videos
Related Concept Videos
01:26Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
01:18Factors Affecting Illness
For instance, risk factors are connected to illness,...
01:15Methods of Documentation VI: Case Management Model
For example, a patient with a chronic...
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History